For Diabetic Macular Edema, Brolucizumab Shows “Robust” Visual, Structural Gains
Two factors in the treatment of diabetic macular edema (DME) are widely known; persistence of fluid can reduce visual acuity outcomes, and monthly intravitreal injections are challenging for patients with multiple comorbidities. The promise of…